基于基因芯片分析的骨肉瘤多靶点研究
Multi-Target Study of Osteosarcoma Based on Microarray Analysis

DOI: 10.12677/HJBM.2019.93016, PP. 107-113

Keywords: 骨肉瘤，基因芯片，多靶向治疗，胶原
Osteosarcoma, Gene Chip, Multi-Target Therapy, Collagen

Full-Text   Cite this paper   Add to My Lib

Abstract:

目的：近年来，标准化和单靶向疗法对骨肉瘤都没有显著效果，因此，多靶向治疗骨肉瘤是目前发展的趋势。方法：通过基因数据库寻找到骨肉瘤相关芯片GSE16088，对正常骨和骨肉瘤芯片中基因的差异表达进行分析，并构建交互网络，最后基于其相互作用性强的基因进行骨肉瘤信号通路机制分析并找出多个靶点。结果：通过对骨肉瘤和正常骨组织基因芯片的差异表达分析，得出其差异表达最强的是胶原(Collagen, COL)系基因，并通过构建交互网络发现其致病相关通路为COL-MMPs-RhoA-JNK通路，基于此通路，可同时进行细胞质机制重塑和药物多靶向治疗。结论：多靶向COL-MMPs-RhoA-JNK通路中的关键基因是治疗骨肉瘤的一个新思路，为临床靶向治疗骨肉瘤提供更多的切入点。
Objective: In recent years, both standardized and single targeting methods have not been effective in the treatment of osteosarcoma; therefore, multi-target therapy is the trend of development on osteosarcoma. Methods: The differentially expressed genes in normal bone and osteosarcoma microarray were analyzed and the interactive network was constructed through searching for osteosarcoma related chip GSE16088 in gene database. Finally, multiple targets were identified based on these highly interacting genes. Results: The strongest differentially expressed genes were collagen (COL) genes based on analyzing the differentially expressed genes between osteosarcoma and normal bone tissues. And the pathogenicity related pathway was COL-MMPs-RhoA-JNK pathway through the construction of interactive network. Conclusion: COL-MMPs-RhoA-JNK pathway could be used to multiple-target osteosarcoma, which provides more ideas for clinical treatment of osteosarcoma.

References

[1]	曾新歆, 王胜涛, 贵鹏, 吴昊, 李朝旭. 骨肉瘤免疫靶向治疗相关机制的研究进展[J]. 中国免疫学杂志, 2019, 35(2): 236-239.
[2]	张德绸, 王廷帆, 葛建华. 骨肉瘤最新治疗及研究进展[J]. 西南医科大学学报, 2018, 41(5): 473-476.
[3]	黄成校, 郭卫春, 郭哲. 骨肉瘤的治疗进展[J]. 医学综述, 2013, 19(11): 1979-1982.
[4]	郭长升, 樊青霞. 骨肉瘤基因研究进展[J]. 中国现代医学杂志, 2011, 21(33): 4158-4164.
[5]	李胜, 王威, 李建军. 骨肉瘤手术治疗方式的研究进展[J]. 山东医药, 2018, 58(32): 95-97.
[6]	刘怀毫, 梁振, 梁沛杰. 骨肉瘤化学治疗的研究进展[J]. 中国临床新医学, 2018, 11(3): 311-314.
[7]	朱翔, 董扬. 骨肉瘤分子生物靶向治疗的研究进展[J]. 中国骨肿瘤骨病, 2011, 10(6): 602-606.
[8]	Ho, X.D., et al. (2017) Whole Transcriptome Analysis Identifies Dif-ferentially Regulated Network between Osteosarcoma and Normal Bone Samples. Experimental Biology and Medicine, 242, 1802-1811. https://doi.org/10.1177/1535370217736512
[9]	Botter, S.M., Neri, D. and Fuchs, B. (2014) Recent Advances in Osteosarcoma. Current Opinion in Pharmacology, 16, 15-23. https://doi.org/10.1016/j.coph.2014.02.002
[10]	王海彬, 樊粤光, 何伟. 人成骨细胞的I型胶原合成及基因表达[J]. 中国中医骨伤科杂志, 2003, 11(4): 11-15.
[11]	聂立华, 孙保勇. 软组织肉瘤靶向治疗药物的研究进展[J]. 山东医药, 2018, 58(16): 104-107.
[12]	喻紫晨, 肖兢, 徐海声. 四肢骨肉瘤患者的治疗及预后分析[J]. 实用癌症杂志, 2014, 29(2): 199-201.
[13]	张熙, 王东伟, 刘爽. Wnt信号通路在骨肉瘤发生机制中作用的研究进展[J]. 实用医学杂志, 2018, 34(23): 4005-4007.
[14]	陈校国, 肖扬, 伍旭辉. 骨肉瘤靶向治疗的研究进展[J]. 西南军医, 2017, 5(19): 438-443.
[15]	王丹, 张涵瑜, 刘亮. 人骨肉瘤发生的分子基础和潜在治疗靶点[J]. 北华大学学报(自然科学版), 2017, 18(6): 747-750.
[16]	陈至鑫, 章静波. 治疗骨肉瘤的潜在靶向蛋白[J]. 基础医学与临床, 2016, 36(1): 29.
[17]	Mohseny, A.B., Cai, Y., Kuijjer, M., et al. (2012) The Activities of Smad and Gli Mediated Signalling Pathways in High-Grade Conventional Osteosarcoma. Eu-ropean Journal of Cancer, 48, 3429-3438. https://doi.org/10.1016/j.ejca.2012.06.018
[18]	Fromigué, O., Hamidouche, Z. and Marie, P.J. (2008) Blockade of the RhoA-JNK-c-Jun-MMP2 Cascade by Atorvastatin Reduces Osteosarcoma Cell Invasion. The Journal of Biological Chemistry, 283, 30549-30556. https://doi.org/10.1074/jbc.M801436200
[19]	Pakos, E.E., Kyzas, P.A. and Ioannidis, J.P. (2004) Prognostic Sig-nificance of TP53 Tumor Suppressor Gene Expression and Mutations in Human Osteosarcoma: A Meta-Analysis. Clinical Cancer Research, 10, 6208-6214. https://doi.org/10.1158/1078-0432.CCR-04-0246
[20]	章磊, 流小舟, 孙畅, 黎承军. 多途径靶向给药系统在骨肉瘤治疗中的研究进展[J]. 东南国防医药, 2016, 18(6): 632-635.
[21]	Kirpensteijn, J., Kik, M., Teske, E. and Rutteman, G.R. (2008) TP53 Gene Mutations in Canine Osteosarcoma. Veterinary Surgery, 37, 454-460. https://doi.org/10.1111/j.1532-950X.2008.00407.x
[22]	Yang, Q.J., Zhou, L.Y., Mu, Y.Q., et al. (2012) All-Trans Retinoic Acid Inhibits Tumor Growth of Human Osteosarcoma by Activating Smad Signaling-Induced Osteogenic Differentiation. International Journal of Oncology, 41, 153-160.

Full-Text